icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
Triplet therapy of cyclophosphamide, thalidomide and dexamethasone (CTD) is standard therapy for relapsed refractory multiple myeloma (RR MM) as it is an oral treatment regimen which is affordable, well tolerated and associated with an overall response rate of 45%. Ixazomib is a proteasome inhibitor and studies of its use as a single agent and in combination therapy have been promising. ITD is a study of the use of oral Ixazomib in combination with thalidomide and dexamethasone.

STUDY DESIGN

Multicentre, open label, prospective, single arm study

CORRELATIVE STUDIES

Blood and bone marrow samples are collected for assessment of minimal residual disease (MRd) and for purification and storage for potential future exploratory biomarker studies

TRIAL PRINCIPAL INVESTIGATOR

Professor Andrew Spencer

TIME FRAME

2016 – 2018

SITE LOCATIONS

  • Alfred Hospital, VIC
  • Flinders Medical Centre, SA

PARTICIPANTS

45 patients with relapsed refractory multiple myeloma (RR MM) who have received 1-3 prior lines of therapy

CURRENT ENROLMENT

40

STATUS

Recruiting